Skip to main content

Iambic

Published

Aug 5, 2025

Tom Miller, CEO of Iambic, sits down with Nasdaq's Chief Client Officer Joe Brantuk to discuss how the company is revolutionizing drug discovery through AI. From its rapid growth and partnership with Revolution Medicines to upcoming clinical milestones and recognition on CNBC’s Disruptor 50 list, Miller shares what sets Iambic apart in the biopharma space.

No transcript available

My Quotes
My European Quotes
Watchlist

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ETFs and more asset classes.

/

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Shares, Indexes, ETP and more asset classes.

/

Edit Watchlist

Your Watchlist is empty.

Create your Watchlist to save your favorite quotes on Nasdaq.com. Log in or create a free account to get started.

/